MLXIPL and metabolic dysfunction-associated steatotic liver disease: In particular, the genes including JNKs, SREBP-1c, ChREBP, PPARs, CYPs, and the others have been highlighted as crucial molecular targets for Danshen treating patients with NAFLD (Figure 4).